If a drug maker tested an asthma treatment in children and found it significantly reduced attacks compared with a placebo, this would be considered good news, yes?
But what if the children enrolled in the clinical trial were almost entirely white, even though asthma disproportionately affects Black and Puerto Rican children?
This would dampen my enthusiasm, to say the least. And it would make me wonder why a company would fail to study enough of the children who are most in need.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.